{
    "SPADE_N_14452": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_14452",
            "Peptide Name": "ParalichenysinDY4 (natural AMPs; bacteriocins; Gram-positive bacteria, prokaryotes; UCLL1)",
            "Source": "Bacillus paralicheniformisDY4;  human microbiota:gut",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "MSGIIRVTPAELRQMADRYQKESGDVTEQVNQRLDQMINQLQDMWEGESSRAFSEQYQELRPSFIKMAELLSDVSKQLHQTANTLESTDQDIASQIRG",
            "Sequence Length": 98,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-MRSA"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 11277.41,
            "PI": 4.64,
            "Hydrophobicity": -0.8,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Wang H, Wang L, Zhang F, Li X, Wang S, Gao D, Li X, Qian P.2024",
                    "Reference": "Int J Biol Macromol. 2024 Sep 6;279(Pt 4):135412. doi: 10.1016/j.ijbiomac.2024.135412.PubMed",
                    "Title": "ParalichenysinDY4, a novel bacteriocin-like substance, is employed to control Clostridium perfringens."
                }
            ],
            "Frequent Amino Acids": "QSE",
            "Absent Amino Acids": "COU",
            "Basic Residues": 11,
            "Acidic Residues": 16,
            "Hydrophobic Residues": 36,
            "Polar Residues": 54,
            "Positive Residues": 11,
            "Negative Residues": 16,
            "Net Charge": -5,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (29.69%) toScygonadin2Q: 13%. GRAVY: -0.796; mol Wt: 11277.571; mol formula: C478H775N138O164S5; mol ex coeff: 8530. This is a unique peptide sequence.Activity: active against Gram+ C. perfringens ATCC 13124 and 8 other strains (MIC 4-8 ug/ml), L. monocytogenes ATCC 19111 (MIC 32 ug/ml), S. aureus ATCC 43300 or  ATCC 29213 (MIC 32-64 ug/ml), S. agalactiae ATCC 13813 (MIC 2 ug/ml), S. suis 0859 (MIC 2 ug/ml), E. faecalis 012-2 (MIC 16 ug/ml), but not Gram- S.Typhimurium ATCC 14028 (MIC > 256 ug/ml), E.coli DH5alpha or K88 or EHEC O157:H7 (MIC >256 ug/ml), A.pleuropneumoniae APP 18 (MIC>256 ug/ml), and  P.aeruginosa ATCC 27853 (MIC>256 ug/ml).Antimicrobial robustness: >90% activity retained after treatment at 80-100oC. pH-insensitive (pH 2-11); insensitive to treatment of pepsin, trypsin, but sensitive to proteinase K.MOA:bacteria:C. perfringens:  permeated membranes.Animal model:mouse: peptide treatment at 50 and 100 mg/kg reduced CFU in mouse small intestine, cecum, and colon 24 h post-infection (orally/orally). More models tested (TBA).",
            "Similar Sequences": []
        }
    }
}